Startup profile · funding coverage
Faro AI funding, valuation and investors
Structured clinical-development data models and agentic AI from protocol intent through execution.
Keep track of Faro AI
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$37.3M · August 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$37M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · San Diego, CA
Overview
Faro AI (formerly Faro Health) is a San Diego clinical-development AI company. It builds proprietary structured data models that represent study concepts, relationships, constraints, and intent so AI agents can reason across clinical workflows rather than treating documents as isolated tasks. On August 26, 2026 Faro announced a $37.3 million Series B co-led by Merck Global Health Innovation Fund and S32, with returning investors including General Catalyst, Northpond Ventures, Polaris Partners, PTX Capital, and Zetta, plus new investor Ankona Capital. Company: platform used by six of the ten largest pharmaceutical companies. No valuation disclosed. Only General Catalyst has a Venture Capital Tracker fund page among named investors.
Why Faro AI is interesting
August 26, 2026: $37.3M Series B co-led by Merck Global Health Innovation Fund and S32, with General Catalyst returning. Company: used by six of the world’s ten largest pharmaceutical companies.
Product & use cases
Clinical-intent substrate starting at the protocol, enabling agents across study design, build, execution, data flows, and regulatory documentation.
- Protocol authoring grounded in structured study intent
- Agent support across clinical development workflows
- Connecting scientific decisions to operational and regulatory constraints
Key facts
- Aug 26, 2026: $37.3M Series B; Merck GHI + S32 co-lead (company)
- General Catalyst returning with Northpond, Polaris, PTX, Zetta; Ankona new
- Company: 6 of top 10 global pharma customers
- Rebrand emphasis: Faro Health → Faro AI
Funding history (newest first)
Series B
2026-08 $37.3M- Merck Global Health Innovation Fund (lead)
- S32 (lead)
- General Catalyst (participant)
Source: https://faro.ai/blog/what-our-series-b-means-for-our-customers
Investors in our directory
Funds linked from Faro AI's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Years of proprietary clinical development data models plus top-pharma footprint — ARR and valuation still undisclosed.
-
Protocol drafting copilots adjacent
Document generation without shared structured intent across the continuum.
-
eClinical / EDC suites incumbent
Trial operations systems of record; Faro positions as AI layer on development intent.
Industries
Related funding articles
Venture Capital Tracker pieces that cover Faro AI's financing or category context.
FAQs about Faro AI
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.